Download PDF
1 / Pages

Other users also viewed these articles

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023 J.E. Meca-Lallana; S. Martínez Yélamos; S. Eichau; M.Á. Llaneza; J. Martín Martínez; J. Peña Martínez; V. Meca Lallana; A.M. Alonso Torres; E. Moral Torres; J. Río; C. Calles; A. Ares Luque; L. Ramió-Torrentà; M.E. Marzo Sola; J.M. Prieto; M.L. Martínez Ginés; R. Arroyo; M.Á. Otano Martínez; L. Brieva Ruiz; M. Gómez Gutiérrez; A. Rodríguez-Antigüedad Zarranz; V.G. Sánchez-Seco; L. Costa-Frossard; M.Á. Hernández Pérez; L. Landete Pascual; M. González Platas; C. Oreja-Guevara;
Neurologia. 2024;39:196-208
Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm G. Valero-López; E. Carreón-Guarnizo; R. Hernández-Clares; F. Iniesta-Martínez; J. Jiménez-Veiga; A. Moreno-Docon; M.A. Iborra-Bendicho; E. Aznar-Robles; M.F. Hellín-Gil; A. Morales-Ortiz; J.E. Meca-Lallana;
Neurologia. 2020;35:357-62
The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis O. Mirmosayyeb; V. Shaygannejad; N. Ebrahimi; H. Ghoshouni; M. Ghajarzadeh;
10.1016/j.nrleng.2022.07.004